{"url_path":"/sec/shfh/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/2032609/0001477932-26-003073-index.html","accession_number":"0001477932-26-003073","cik":"0002032609","ticker":"SHFH","issuer_name":"Scientist Home Future Health Ltd","edgar_url":"https://www.sec.gov/Archives/edgar/data/2032609/0001477932-26-003073-index.html","primary_entity_key":"0002032609","primary_entity_name":"Scientist Home Future Health Ltd"},"word_count":567,"has_tables":true,"body_markdown":"scientist_10q.htm\n0002032609false--12-31Q12026898010.00012000000002371600023716000falsefalsefalsefalse000020326092026-01-012026-03-310002032609scientist:NonHongKongMember2025-03-310002032609scientist:NonHongKongMember2026-03-310002032609scientist:NonHongKongMember2025-01-012025-03-310002032609scientist:NonHongKongMember2026-01-012026-03-310002032609scientist:HongKongMember2025-03-310002032609scientist:ServiceBusinessMember2026-03-310002032609scientist:ServiceBusinessMember2026-01-012026-03-310002032609scientist:RetailTradingBusinessBMember2025-03-310002032609scientist:RetailTradingBusinessBMember2026-03-310002032609scientist:RetailTradingBusinessBMember2025-01-012025-03-310002032609scientist:RetailTradingBusinessBMember2026-01-012026-03-310002032609scientist:CustomerConcentrationMember2025-01-012025-03-310002032609scientist:CustomerConcentrationMember2026-01-012026-03-310002032609scientist:VendorAMember2025-01-012025-03-310002032609scientist:VendorAMember2026-01-012026-03-310002032609scientist:RelatedPartyBMember2026-01-012026-03-310002032609scientist:RelatedPartyBFinancingMember2026-03-310002032609scientist:RelatedPartyBFinancingMember2025-12-310002032609scientist:RelatedPartyBOperatingMember2025-12-310002032609scientist:RelatedPartyBOperatingMember2026-03-310002032609scientist:RoomBThreeMember2026-01-012026-03-310002032609scientist:ThreeFMowHingIndustrialBuildingMember2026-01-012026-03-310002032609scientist:HongKongMember2026-03-310002032609scientist:MarshallIslandsMember2026-03-310002032609scientist:HongKongMember2025-12-310002032609scientist:MarshallIslandsMember2025-12-310002032609us-gaap:DomesticCountryMember2025-12-310002032609us-gaap:DomesticCountryMember2026-03-310002032609scientist:HongKongMember2026-01-012026-03-310002032609scientist:MarshallIslandsMember2026-01-012026-03-310002032609scientist:HongKongMember2025-01-012025-03-310002032609scientist:MarshallIslandsMember2025-01-012025-03-310002032609scientist:LocalMember2025-01-012025-03-310002032609scientist:LocalMember2026-01-012026-03-310002032609srt:DirectorMember2025-12-310002032609srt:DirectorMember2026-03-310002032609scientist:InvestorsMember2024-01-012024-12-310002032609scientist:MrChanSiuHungMember2024-07-012024-07-030002032609scientist:MrChanSiuHungMember2024-08-022024-08-140002032609scientist:MrChanSiuHungMember2024-08-140002032609scientist:MrChanSiuHungMember2024-07-030002032609scientist:InvestorsMember2024-12-310002032609us-gaap:MachineryAndEquipmentMember2026-03-310002032609us-gaap:ComputerEquipmentMember2026-03-310002032609us-gaap:MachineryAndEquipmentMember2025-12-310002032609us-gaap:ComputerEquipmentMember2025-12-310002032609us-gaap:OfficeEquipmentMember2025-12-310002032609us-gaap:OfficeEquipmentMember2026-03-310002032609scientist:LeaseTwoMember2025-01-012025-12-310002032609scientist:LeaseOneMember2025-01-012025-12-3100020326092025-01-012025-12-310002032609scientist:ScientistHomeHighConcentrationProteinaseMember2025-01-012025-03-310002032609scientist:ScientistHomeSpermacetiCreamMember2025-01-012025-03-310002032609scientist:ScientistHomeChelationStudyMember2026-01-012026-03-310002032609scientist:ScientistHomeFibrosisStudyMember2026-01-012026-03-310002032609scientist:ScientistHomeImmuneStudyMember2026-01-012026-03-310002032609scientist:ScientistHomeCholipolysisCholicAcidMember2026-01-012026-03-310002032609scientist:ScientistHomeCalcificationCreamMember2025-01-012025-03-310002032609scientist:OthersDeliveryFeeMember2026-01-012026-03-310002032609scientist:OthersDeliveryFeeMember2025-01-012025-03-310002032609scientist:ScientistHomeBoneGelatineHydrolysateMember2025-01-012025-03-310002032609scientist:ScientistHomeVeinCreamMember2025-01-012025-03-310002032609scientist:ScientistHomeMixedGelatineHydrolysateMember2025-01-012025-03-310002032609scientist:ScientistHomeMixedGelatineHydrolysateMember2026-01-012026-03-310002032609us-gaap:OfficeEquipmentMember2026-01-012026-03-310002032609us-gaap:MachineryAndEquipmentMember2026-01-012026-03-310002032609us-gaap:ComputerEquipmentMember2026-01-012026-03-310002032609scientist:ScientistHomeFutureHealthLimitedMember2024-09-260002032609scientist:ScientistHomeFutureHealthHoldingLimitedMember2026-03-310002032609scientist:ScientistHomeFutureHealthLimitedMember2026-01-012026-03-310002032609scientist:ScientistHomeFutureHealthHoldingLimitedMember2026-01-012026-03-310002032609us-gaap:RetainedEarningsMember2026-03-310002032609us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-03-310002032609us-gaap:AdditionalPaidInCapitalMember2026-03-310002032609us-gaap:CommonStockMember2026-03-310002032609us-gaap:RetainedEarningsMember2026-01-012026-03-310002032609us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-01-012026-03-310002032609us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-310002032609us-gaap:CommonStockMember2026-01-012026-03-310002032609us-gaap:RetainedEarningsMember2025-12-310002032609us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-310002032609us-gaap:AdditionalPaidInCapitalMember2025-12-310002032609us-gaap:CommonStockMember2025-12-3100020326092025-03-310002032609us-gaap:RetainedEarningsMember2025-03-310002032609us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-310002032609us-gaap:AdditionalPaidInCapitalMember2025-03-310002032609us-gaap:CommonStockMember2025-03-310002032609us-gaap:RetainedEarningsMember2025-01-012025-03-310002032609us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310002032609us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310002032609us-gaap:CommonStockMember2025-01-012025-03-3100020326092024-12-310002032609us-gaap:RetainedEarningsMember2024-12-310002032609us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310002032609us-gaap:AdditionalPaidInCapitalMember2024-12-310002032609us-gaap:CommonStockMember2024-12-3100020326092025-01-012025-03-3100020326092025-12-3100020326092026-03-31iso4217:USDxbrli:sharesiso4217:USDxbrli:sharesxbrli:pure\n\n  \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n \n\n**FORM 10-Q**\n\n \n\n(Mark One)\n\n \n\n☒\n\nQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\n \n\n**For the quarterly period ended** **March 31, 2026**\n\n \n\nOr\n\n \n\n☐\n\nTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\n \n\nFor the transition period from ______ to ______\n\n \n\nCommission file number **333-283430**\n\n \n\n**Scientist Home Future Health Limited**\n\n(Exact name of registrant as specified in its charter)\n\n \n\n**Nevada**\n\n \n\n**30-1416636**\n\n(State or other jurisdiction of\n\nincorporation or organization)\n\n \n\n(I.R.S. Employer\n\nIdentification No.)\n\n \n\n**2844**\n\n(Primary Standard Industrial Classification Code Number)\n\n \n\n**Room B3, Block B, 3/F, Mow Hing Industrial Building, 205 Wai Yip Street,**\n\n**Kwun Tong, Kowloon, Hong Kong**\n\n(Address of principal executive offices)\n\n \n\nRegistrant’s telephone number, including area code: **+852 5702 3076**\n\n \n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n \n\n**Title of each class**\n\n \n\n**Trading Symbol(s)**\n\n \n\n**Name of exchange on which registered**\n\nN/A\n\n \n\nN/A\n\n \n\nN/A\n\n \n\nIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes     ☐ No\n\n \n\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes     ☐ No\n\n \n\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n \n\nLarge accelerated filer\n\n☐\n\nAccelerated filer\n\n☐\n\nNon-accelerated Filer\n\n☒\n\nSmaller reporting company\n\n☒\n\n \n\n \n\nEmerging growth company\n\n☒\n\n \n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act.) ☐ Yes     ☒ No\n\n \n\nAPPLICABLE ONLY TO CORPORATE ISSUERS\n\n \n\nIndicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.\n\n \n\nThe number of shares outstanding of the registrant’s common stock as of March 31, 2026 was 23,716,000 shares.\n\n \n\n \n\n \n\n \n\n**SCIENTIST HOME FUTURE HEALTH LIMITED**\n\n \n\n**QUARTERLY REPORT ON FORM 10-Q**\n\n \n\n**For the three months ended March 31, 2026**\n\n \n\n[**Part I – FINANCIAL INFORMATION**](#p1)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n[Item 1.](#i1)\n\n[Financial Statements (unaudited)](#i1)\n\n \n\nF-1 - F-19\n\n \n\n \n\n \n\n \n\n \n\n \n\n[Item 2.](#i2)\n\n[Management’s Discussion and Analysis of Financial Conditions and Results of Operations](#i2)\n\n \n\n3\n\n \n\n \n\n \n\n \n\n \n\n \n\n[Item 3.](#i3)\n\n[Quantitative and Qualitative Disclosures about Market Risk](#i3)\n\n \n\n7\n\n \n\n \n\n \n\n \n\n \n\n \n\n[Item 4.](#i4)\n\n[Controls and Procedures](#i4)\n\n \n\n7\n\n \n\n \n\n \n\n \n\n \n\n \n\n[**Part II – OTHER INFORMATION**](#p2)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n[Item 1.](#p2i1)\n\n[Legal Proceedings](#p2i1)\n\n \n\n9\n\n \n\n \n\n \n\n \n\n \n\n \n\n[Item 1A.](#p2i1a)\n\n[Risk Factors](#p2i1a)\n\n \n\n9\n\n \n\n \n\n \n\n \n\n \n\n \n\n[Item 2.](#p2i2)\n\n[Unregistered Sales of Equity Securities and Use of Proceeds](#p2i2)\n\n \n\n9\n\n \n\n \n\n \n\n \n\n \n\n \n\n[Item 3.](#p2i3)\n\n[Defaults Upon Senior Securities](#p2i3)\n\n \n\n9\n\n \n\n \n\n \n\n \n\n \n\n \n\n[Item 4.](#p2i4)\n\n[Mine Safety Disclosures](#p2i4)\n\n \n\n9\n\n \n\n \n\n \n\n \n\n \n\n \n\n[Item 5.](#p2i5)\n\n[Other Information](#p2i5)\n\n \n\n9\n\n \n\n \n\n \n\n \n\n \n\n \n\n[Item 6.](#p2i6)\n\n[Exhibits](#p2i6)\n\n \n\n10\n\n \n\n \n\n \n\n \n\n \n\n \n\n[**SIGNATURES**](#sig)\n\n \n\n11\n\n \n\n \n\n \n\n2\n\n*Table of Contents*\n\n  \n\n**PART I FINANCIAL INFORMATION**"}